71
1.
Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman
DS, et al. Causes and prevalence of visual impairment among adults in the
United States. Arch Ophthalmol. 2004;122(4):477-85. Epub 2004/04/14. doi:
10.1001/archopht.122.4.477. PubMed PMID: 15078664.
2.
Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al.
EVEREST study: efficacy and safety of verteporfin photodynamic therapy in
combination with ranibizumab or alone versus ranibizumab monotherapy in
patients with symptomatic macular polypoidal choroidal vasculopathy.
Retina. 2012;32(8):1453-64. doi: 10.1097/IAE.0b013e31824f91e8. PubMed
PMID: 22426346.
3.
Pascolini D, Mariotti SP, Pokharel GP, Pararajasegaram R, Etya'ale
D, Négrel AD, et al. 2002 global update of available data on visual
impairment:
compilation
Ophthalmic
Epidemiol.
of
population-based
2004;11(2):67-115.
prevalence
Epub
studies.
2004/07/17.
doi:
10.1076/opep.11.2.67.28158. PubMed PMID: 15255026.
4.
Miyazaki M, Kiyohara Y, Yoshida A, Iida M, Nose Y, Ishibashi T. The
5-year incidence and risk factors for age-related maculopathy in a general
Japanese population: the Hisayama study. Invest Ophthalmol Vis Sci.
2005;46(6):1907-10. Epub 2005/05/26. doi: 10.1167/iovs.04-0923. PubMed
PMID: 15914602.
5.
Leal S, Silva R, Figueira J, Cachulo ML, Pires I, de Abreu JR, et al.
Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy:
results after 3 years of follow-up. Retina. 2010;30(8):1197-205. doi:
10.1097/IAE.0b013e3181d37486. PubMed PMID: 20827139.
6.
Liu L, Hu C, Chen L, Hu Y. Photodynamic therapy for symptomatic
circumscribed choroidal hemangioma in 22 Chinese patients: A retrospective
study.
Photodiagnosis
Photodyn
Ther.
2018;24:372-6.
doi:
10.1016/j.pdpdt.2018.10.019. PubMed PMID: 30381258.
7.
Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH.
Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye
Res. 2013;37:182-99. doi: 10.1016/j.preteyeres.2013.09.003. PubMed PMID:
24140257.
8.
Tano Y, Ophthalmic PDTSG. Guidelines for PDT in Japan.
Ophthalmology. 2008;115(3):585- e6. doi: 10.1016/j.ophtha.2007.10.018.
72
PubMed PMID: 18319105.
9.
Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund
KB. Pachychoroid disease. Eye (Lond). 2018. doi: 10.1038/s41433-018-0158-4.
PubMed PMID: 29995841.
10.
Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund
KB. Pachychoroid disease. Eye (Lond). 2019;33(1):14-33. doi: 10.1038/s41433018-0158-4.
PubMed
PMID:
29995841;
PubMed
Central
PMCID:
PMCPMC6328576.
11.
Hata M, Yamashiro K, Ooto S, Oishi A, Tamura H, Miyata M, et al.
Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid
Neovasculopathy and Neovascular Age-Related Macular Degeneration.
Invest Ophthalmol Vis Sci. 2017;58(1):292-8. doi: 10.1167/iovs.16-20967.
PubMed PMID: 28114590.
12.
Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina.
2015;35(1):1-9.
doi:
10.1097/IAE.0000000000000331.
PubMed
PMID:
25158945.
13.
Kawashima Y, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ueda-
Arakawa N, et al. Effects of aflibercept for ranibizumab-resistant neovascular
age-related macular degeneration and polypoidal choroidal vasculopathy.
Graefes Arch Clin Exp Ophthalmol. 2014. doi: 10.1007/s00417-014-2838-5.
PubMed PMID: 25391986.
14.
Kang HM, Koh HJ, Lee CS, Lee SC. Combined photodynamic
therapy with intravitreal bevacizumab injections for polypoidal choroidal
vasculopathy: long-term visual outcome. Am J Ophthalmol. 2014;157(3):598606 e1. doi: 10.1016/j.ajo.2013.11.015. PubMed PMID: 24269378.
15.
Wang W, He M, Zhang X. Combined intravitreal anti-VEGF and
photodynamic therapy versus photodynamic monotherapy for polypoidal
choroidal
vasculopathy:
comparative
studies.
systematic
PLoS
review
One.
and
meta-analysis
2014;9(10):e110667.
of
doi:
10.1371/journal.pone.0110667. PubMed PMID: 25343244; PubMed Central
PMCID: PMCPMC4208801.
16.
Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H,
Fukushima I, et al. Polypoidal choroidal vasculopathy: natural history. Am J
Ophthalmol.
2002;133(5):639-48.
doi:
73
10.1016/s0002-9394(02)01404-6.
PubMed PMID: 11992861.
17.
Azuma K, Obata R, Nomura Y, Tan X, Takahashi H, Yanagi Y.
Angiographic Findings of Ranibizumab-Resistant Polypoidal Choroidal
Vasculopathy after Switching to a Treat-and-Extend Regimen with
Intravitreal
Aflibercept.
Retina.
2016;36(11):2158-65.
doi:
10.1097/IAE.0000000000001047. PubMed PMID: 27258669.
18.
Miyake M, Ooto S, Yamashiro K, Takahashi A, Yoshikawa M, Akagi-
Kurashige Y, et al. Pachychoroid neovasculopathy and age-related macular
degeneration. Sci Rep. 2015;5:16204. doi: 10.1038/srep16204. PubMed PMID:
26542071; PubMed Central PMCID: PMCPMC4635432.
19.
Miyake M, Tsujikawa A, Yamashiro K, Ooto S, Oishi A, Tamura H,
et al. Choroidal neovascularization in eyes with choroidal vascular
hyperpermeability. Invest Ophthalmol Vis Sci. 2014;55(5):3223-30. doi:
10.1167/iovs.14-14059. PubMed PMID: 24781946.
20.
Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year
outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and
HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology.
2013;120(11):2292-9. Epub 2013/05/07. doi: 10.1016/j.ophtha.2013.03.046.
PubMed PMID: 23642856.
21.
Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA.
Polypoidal
choroidal
vasculopathy:
review.
Surv
Ophthalmol.
2010;55(6):501-15. doi: 10.1016/j.survophthal.2010.03.004. PubMed PMID:
20850857.
22.
Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock
DA. The expanding clinical spectrum of idiopathic polypoidal choroidal
vasculopathy. Arch Ophthalmol. 1997;115(4):478-85. PubMed PMID: 9109756.
23.
Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal
choroidal vasculopathy (IPCV). Retina. 1990;10(1):1-8. PubMed PMID:
1693009.
24.
Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K.
Indocyanine green angiographic and optical coherence tomographic findings
support classification of polypoidal choroidal vasculopathy into two types.
Acta Ophthalmol. 2013;91(6):e474-81. doi: 10.1111/aos.12110. PubMed PMID:
23848133.
74
25.
Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related
macular degeneration. Lancet. 2012;379(9827):1728-38. doi: 10.1016/S01406736(12)60282-7. PubMed PMID: 22559899.
26.
Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related
maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology.
1995;102(10):1450-60. PubMed PMID: 9097791.
27.
Byeon SH, Lee SC, Oh HS, Kim SS, Koh HJ, Kwon OW. Incidence
and clinical patterns of polypoidal choroidal vasculopathy in Korean patients.
Jpn J Ophthalmol. 2008;52(1):57-62. doi: 10.1007/s10384-007-0498-2.
PubMed PMID: 18369702.
28.
Lim TH, Laude A, Tan CS. Polypoidal choroidal vasculopathy: an
angiographic
discussion.
Eye
(Lond).
2010;24(3):483-90.
doi:
10.1038/eye.2009.323. PubMed PMID: 20075967.
29.
Liu Y, Wen F, Huang S, Luo G, Yan H, Sun Z, et al. Subtype lesions
of neovascular age-related macular degeneration in Chinese patients. Graefes
Arch Clin Exp Ophthalmol. 2007;245(10):1441-5. doi: 10.1007/s00417-0070575-8. PubMed PMID: 17406882.
30.
Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical
characteristics of exudative age-related macular degeneration in Japanese
patients. Am J Ophthalmol. 2007;144(1):15-22. doi: 10.1016/j.ajo.2007.03.047.
PubMed PMID: 17509509.
31.
Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, et al.
Polypoidal choroidal vasculopathy: incidence, demographic features, and
clinical
characteristics.
Arch
Ophthalmol.
2003;121(10):1392-6.
doi:
10.1001/archopht.121.10.1392. PubMed PMID: 14557174.
32.
Kikuchi M, Nakamura M, Ishikawa K, Suzuki T, Nishihara H,
Yamakoshi T, et al. Elevated C-reactive protein levels in patients with
polypoidal choroidal vasculopathy and patients with neovascular age-related
macular
degeneration.
Ophthalmology.
2007;114(9):1722-7.
doi:
10.1016/j.ophtha.2006.12.021. PubMed PMID: 17400294.
33.
Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K,
Matsumura M. Expression of pigment epithelium derived factor and vascular
endothelial growth factor in choroidal neovascular membranes and
polypoidal choroidal vasculopathy. Br J Ophthalmol. 2004;88(6):809-15.
75
PubMed PMID: 15148217; PubMed Central PMCID: PMC1772169.
34.
Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T.
Polypoidal choroidal vasculopathy treated with macular translocation:
clinical pathological correlation. Br J Ophthalmol. 2002;86(3):321-7. PubMed
PMID: 11864892; PubMed Central PMCID: PMC1771039.
35.
Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, et al.
Aqueous humor levels of vascular endothelial growth factor and pigment
epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal
neovascularization.
Am
Ophthalmol.
2006;141(3):456-62.
doi:
10.1016/j.ajo.2005.10.012. PubMed PMID: 16490490.
36.
Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, et al.
Comparison of the effect of ranibizumab and verteporfin for polypoidal
choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol.
2013;156(4):644-51. doi: 10.1016/j.ajo.2013.05.024. PubMed PMID: 23876867.
37.
Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J,
et al. Treatment of polypoidal choroidal vasculopathy with photodynamic
therapy. Retina. 2002;22(5):529-35. PubMed PMID: 12441716.
38.
Tomita K, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Otani A, et
al. Treatment of polypoidal choroidal vasculopathy with photodynamic
therapy combined with intravitreal injections of ranibizumab. Am J
Ophthalmol. 2012;153(1):68-80 e1. doi: 10.1016/j.ajo.2011.07.001. PubMed
PMID: 21907965.
39.
Akaza E, Yuzawa M, Mori R. Three-year follow-up results of
photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J
Ophthalmol. 2011;55(1):39-44. doi: 10.1007/s10384-010-0886-x. PubMed
PMID: 21331691.
40.
Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A,
et al. Two-year results of photodynamic therapy for polypoidal choroidal
vasculopathy.
Am
Ophthalmol.
2008;146(4):513-9.
doi:
10.1016/j.ajo.2008.05.025. PubMed PMID: 18614133.
41.
Lee WK, Kim KS, Kim W, Lee SB, Jeon S. Responses to
photodynamic therapy in patients with polypoidal choroidal vasculopathy
consisting of polyps resembling grape clusters. Am J Ophthalmol.
2012;154(2):355-65 e1. doi: 10.1016/j.ajo.2012.02.019. PubMed PMID:
76
22541658.
42.
Ojima Y, Tsujikawa A, Otani A, Hirami Y, Aikawa H, Yoshimura N.
Recurrent bleeding after photodynamic therapy in polypoidal choroidal
vasculopathy.
Am
Ophthalmol.
2006;141(5):958-60.
doi:
10.1016/j.ajo.2005.12.002. PubMed PMID: 16678520.
43.
Tsujikawa A, Hirami Y, Nakanishi H, Ojima Y, Aikawa H, Tamura
H, et al. Retinal pigment epithelial tear in polypoidal choroidal vasculopathy.
Retina. 2007;27(7):832-8. doi: 10.1097/IAE.0b013e318150d864. PubMed
PMID: 17891005.
44.
Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic
therapy of polypoidal choroidal vasculopathy. Retina. 2008;28(5):717-22. doi:
10.1097/IAE.0b013e31816577cb. PubMed PMID: 18463515.
45.
Cho HJ, Kim JW, Lee DW, Cho SW, Kim CG. Intravitreal
bevacizumab and ranibizumab injections for patients with polypoidal
choroidal
vasculopathy.
Eye
(Lond).
2012;26(3):426-33.
doi:
10.1038/eye.2011.324. PubMed PMID: 22173075; PubMed Central PMCID:
PMC3298981.
46.
Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R,
Takami K, et al. Results of 2 years of treatment with as-needed ranibizumab
reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol.
2013;97(5):617-21. doi: 10.1136/bjophthalmol-2012-302652. PubMed PMID:
23428984; PubMed Central PMCID: PMC3632979.
47.
Lai TY, Chan WM, Liu DT, Luk FO, Lam DS. Intravitreal
bevacizumab (Avastin) with or without photodynamic therapy for the
treatment
of
polypoidal
choroidal
vasculopathy.
Br
Ophthalmol.
2008;92(5):661-6. doi: 10.1136/bjo.2007.135103. PubMed PMID: 18356265.
48.
Shima C, Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Tano Y. One-
year results of combined photodynamic therapy and intravitreal bevacizumab
injection for retinal pigment epithelial detachment secondary to age-related
macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247(7):899906. doi: 10.1007/s00417-009-1067-9. PubMed PMID: 19308441.
49.
Hikichi T, Kitamei H, Shioya S, Higuchi M, Matsushita T, Kosaka S,
et al. Relation between changes in foveal choroidal thickness and 1-year
results of ranibizumab therapy for polypoidal choroidal vasculopathy. Br J
77
Ophthalmol. 2014;98(9):1201-4. doi: 10.1136/bjophthalmol-2013-304555.
PubMed PMID: 24723615.
50.
Inoue M, Arakawa A, Yamane S, Kadonosono K. Long-term outcome
of intravitreal ranibizumab treatment, compared with photodynamic therapy,
in
patients
with
polypoidal
choroidal
vasculopathy.
Eye
(Lond).
2013;27(9):1013-20; quiz 21. doi: 10.1038/eye.2013.179. PubMed PMID:
23970023; PubMed Central PMCID: PMC3772374.
51.
Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ,
Harding SP. Polypoidal choroidal vasculopathy masquerading as neovascular
age-related macular degeneration refractory to ranibizumab. Am J
Ophthalmol. 2010;150(5):666-73. doi: 10.1016/j.ajo.2010.05.035. PubMed
PMID: 20719300.
52.
Inoue M, Arakawa A, Yamane S, Kadonosono K. Short-term efficacy
of intravitreal aflibercept in treatment-naive patients with polypoidal
choroidal
vasculopathy.
Retina.
2014;34(11):2178-84.
doi:
10.1097/IAE.0000000000000229. PubMed PMID: 25046397.
53.
Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T. Switching to
intravitreal aflibercept injection for polypoidal choroidal vasculopathy
refractory
to
ranibizumab.
Retina.
2014;34(11):2192-201.
doi:
10.1097/IAE.0000000000000236. PubMed PMID: 25077530.
54.
Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo
CD. A treat and extend regimen using ranibizumab for neovascular agerelated macular degeneration clinical and economic impact. Ophthalmology.
2010;117(11):2134-40. doi: 10.1016/j.ophtha.2010.02.032. PubMed PMID:
20591490.
55.
Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel
P, et al. Inject and extend dosing versus dosing as needed: a comparative
retrospective study of ranibizumab in exudative age-related macular
degeneration. Retina. 2011;31(1):26-30. doi: 10.1097/IAE.0b013e3181de5609.
PubMed PMID: 20890246.
56.
Rush RB, Simunovic MP, Vandiver L, Aragon AV, 2nd, Ysasaga JE.
Treat-and-extend
degeneration:
the
bevacizumab
importance
for
of
neovascular
baseline
age-related
characteristics.
macular
Retina.
2014;34(5):846-52. doi: 10.1097/IAE.0000000000000033. PubMed PMID:
78
24240560.
57.
Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo
CD. Bevacizumab for neovascular age-related macular degeneration using a
treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol.
2012;153(3):468-73 e1. doi: 10.1016/j.ajo.2011.08.011. PubMed PMID:
21996309.
58.
Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Tano Y. Marked
vascular changes of polypoidal choroidal vasculopathy after photodynamic
therapy. Br J Ophthalmol. 2008;92(7):936-40. doi: 10.1136/bjo.2007.132357.
PubMed PMID: 18577645.
59.
Fan NW, Lau LI, Chen SJ, Yang CS, Lee FL. Comparison of the effect
of reduced-fluence photodynamic therapy with intravitreal bevacizumab and
standard-fluence alone for polypoidal choroidal vasculopathy. J Chin Med
Assoc. 2014;77(2):101-7. doi: 10.1016/j.jcma.2013.10.012. PubMed PMID:
24332412.
60.
Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, et
al. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal
Vasculopathy.
Ophthalmology.
2015;122(9):1866-72.
doi:
10.1016/j.ophtha.2015.05.024. PubMed PMID: 26088619.
61.
Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, et al.
Aflibercept therapy for exudative age-related macular degeneration resistant
to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):15-22 e1.
doi: 10.1016/j.ajo.2013.02.017. PubMed PMID: 23706500.
62.
Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar
W, et al. Intravitreal aflibercept for treatment-resistant neovascular agerelated macular degeneration. Ophthalmology. 2014;121(1):188-92. doi:
10.1016/j.ophtha.2013.08.035. PubMed PMID: 24144450.
63.
Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, et al.
Short-term outcomes of aflibercept for neovascular age-related macular
degeneration in eyes previously treated with other vascular endothelial
growth factor inhibitors. Am J Ophthalmol. 2013;156(1):23-8 e2. doi:
10.1016/j.ajo.2013.02.009. PubMed PMID: 23664153; PubMed Central
PMCID: PMC4177078.
64.
Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, et
79
al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with
persistent subfoveal fluid despite previous treatments with ranibizumab in
patients with neovascular age-related macular degeneration. Retina.
2013;33(8):1605-12. doi: 10.1097/IAE.0b013e31828e8551. PubMed PMID:
23549101.
65.
Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott
D, et al. Conversion to aflibercept for chronic refractory or recurrent
neovascular
age-related
2013;156(1):29-35
e2.
macular
doi:
degeneration.
Am
10.1016/j.ajo.2013.03.030.
Ophthalmol.
PubMed
PMID:
23668679.
66.
Rush RB, Rush SW, Aragon AV, 2nd, Ysasaga JE. Evaluation of
choroidal neovascularization with indocyanine green angiography in
neovascular
age-related
macular
degeneration
subjects
undergoing
intravitreal bevacizumab therapy. Am J Ophthalmol. 2014;158(2):337-44. doi:
10.1016/j.ajo.2014.05.007. PubMed PMID: 24844972.
67.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY,
et al. Ranibizumab versus verteporfin for neovascular age-related macular
degeneration.
Engl
Med.
2006;355(14):1432-44.
doi:
10.1056/NEJMoa062655. PubMed PMID: 17021319.
68.
Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prunte C, Schmidt-
Erfurth U, et al. Ranibizumab (Lucentis) in neovascular age-related macular
degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94(1):2-13.
doi: 10.1136/bjo.2009.159160. PubMed PMID: 19443462.
69.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY,
et al. Ranibizumab for neovascular age-related macular degeneration. N Engl
J Med. 2006;355(14):1419-31. doi: 10.1056/NEJMoa054481. PubMed PMID:
17021318.
70.
Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment
epithelial)
neovascularization
in
central
serous
chorioretinopathy
masquerading as neovascular age-related macular degeneration. Retina.
2012;32(9):1829-37. doi: 10.1097/IAE.0b013e3182680a66. PubMed PMID:
22850219.
71.
Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S. Relationship
between clinical characteristics of polypoidal choroidal vasculopathy and
80
choroidal vascular hyperpermeability. Am J Ophthalmol. 2013;155(2):305-13
e1. doi: 10.1016/j.ajo.2012.07.018. PubMed PMID: 23022162.
72.
Cho HJ, Kim HS, Jang YS, Han JI, Lew YJ, Lee TG, et al. Effects of
choroidal vascular hyperpermeability on anti-vascular endothelial growth
factor treatment for polypoidal choroidal vasculopathy. Am J Ophthalmol.
2013;156(6):1192-200 e1. doi: 10.1016/j.ajo.2013.07.001. PubMed PMID:
24011522.
73.
Nomura Y, Yanagi Y. Intravitreal aflibercept for ranibizumab-
resistant exudative age-related macular degeneration with choroidal
vascular hyperpermeability. Jpn J Ophthalmol. 2015;59(4):261-5. doi:
10.1007/s10384-015-0387-z. PubMed PMID: 25983109.
74.
Terao N, Koizumi H, Kojima K, Yamagishi T, Yamamoto Y, Yoshii K,
et al. Distinct Aqueous Humour Cytokine Profiles of Patients with
Pachychoroid Neovasculopathy and Neovascular Age-related Macular
Degeneration. Sci Rep. 2018;8(1):10520. doi: 10.1038/s41598-018-28484-w.
PubMed PMID: 30002400; PubMed Central PMCID: PMCPMC6043533.
75.
Sonoda S, Sakamoto T, Yamashita T, Uchino E, Kawano H,
Yoshihara N, et al. Luminal and stromal areas of choroid determined by
binarization method of optical coherence tomographic images. Am J
Ophthalmol. 2015;159(6):1123-31 e1. doi: 10.1016/j.ajo.2015.03.005. PubMed
PMID: 25790737.
76.
Cicchetti D. Guidelines, Criteria, and Rules of Thumb for Evaluating
Normed and Standardized Assessment Instrument in Psychology1994. 28490 p.
77.
Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H.
Efficacy of treat-and-extend regimen with aflibercept for pachychoroid
neovasculopathy and Type 1 neovascular age-related macular degeneration.
Jpn J Ophthalmol. 2018;62(2):144-50. doi: 10.1007/s10384-018-0562-0.
PubMed PMID: 29411171.
78.
Yamamoto A, Okada AA, Nakayama M, Yoshida Y, Kobayashi H.
One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for
Exudative
Age-Related
Macular
Degeneration.
Ophthalmologica.
2017;237(3):139-44. doi: 10.1159/000458538. PubMed PMID: 28259869.
79.
Burnham KP, Anderson DR. P values are only an index to evidence:
81
20th- vs. 21st-century statistical science. Ecology. 2014;95(3):627-30. PubMed
PMID: 24804444.
80.
Mallows
CL.
Some
Comments
on
p.
Technometrics.
1973;15(4):661-75. doi: 10.1080/00401706.1973.10489103.
81.
Tibshirani RJ, Taylor J. Degrees of freedom in lasso problems. Ann
Statist. 2012;40(2):1198-232. doi: 10.1214/12-AOS1003.
82.
Asano S, Azuma K, Shimizu K, Yamamoto R, Lee J, Murata H, et al.
Choroidal structure as a biomarker for visual acuity in intravitreal
aflibercept therapy for polypoidal choroidal vasculopathy. PLoS One.
2018;13(5):e0197042. doi: 10.1371/journal.pone.0197042. PubMed PMID:
29746511; PubMed Central PMCID: PMCPMC5945009.
83.
Ting DSW, Yanagi Y, Agrawal R, Teo HY, Seen S, Yeo IYS, et al.
Choroidal Remodeling in Age-related Macular Degeneration and Polypoidal
Choroidal
Vasculopathy:
12-month
Prospective
Study.
Sci
Rep.
2017;7(1):7868. doi: 10.1038/s41598-017-08276-4. PubMed PMID: 28801615;
PubMed Central PMCID: PMCPMC5554201.
84.
Stewart MW, Rosenfeld PJ. Predicted biological activity of
intravitreal
VEGF
Trap.
Br
Ophthalmol.
2008;92(5):667-8.
doi:
10.1136/bjo.2007.134874. PubMed PMID: 18356264.
85.
al.
Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, et
Subfoveal
Choroidal
Thickness
during
Aflibercept
Therapy
for
Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Ophthalmology.
2016;123(3):617-24.
doi:
10.1016/j.ophtha.2015.10.039.
PubMed PMID: 26686967.
86.
Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal
choroidal thickness after ranibizumab therapy for neovascular age-related
macular degeneration: 12-month results. Ophthalmology. 2012;119(8):1621-7.
doi: 10.1016/j.ophtha.2012.02.022. PubMed PMID: 22551738.
87.
Kinoshita T, Mitamura Y, Mori T, Akaiwa K, Semba K, Egawa M, et
al. Changes in Choroidal Structures in Eyes with Chronic Central Serous
Chorioretinopathy after Half-Dose Photodynamic Therapy. PLoS One.
2016;11(9):e0163104. doi: 10.1371/journal.pone.0163104. PubMed PMID:
27636093; PubMed Central PMCID: PMCPMC5026334.
88.
Kuroda Y, Ooto S, Yamashiro K, Oishi A, Nakanishi H, Tamura H, et
82
al. Increased Choroidal Vascularity in Central Serous Chorioretinopathy
Quantified Using Swept-Source Optical Coherence Tomography. Am J
Ophthalmol. 2016;169:199-207. doi: 10.1016/j.ajo.2016.06.043. PubMed
PMID: 27394034.
89.
Shin MC, Lim JW. Concentration of cytokines in the aqueous humor
of patients with central serous chorioretinopathy. Retina. 2011;31(9):1937-43.
doi: 10.1097/IAE.0b013e31820a6a17. PubMed PMID: 21478806.
90.
Lee JH, Lee WK. One-Year Results of Adjunctive Photodynamic
Therapy for Type 1 Neovascularization Associated with Thickened Choroid.
Retina. 2016;36(5):889-95. doi: 10.1097/IAE.0000000000000809. PubMed
PMID: 27115853.
91.
Bessho H, Honda S, Imai H, Negi A. Natural course and funduscopic
findings of polypoidal choroidal vasculopathy in a Japanese population over
year
of
follow-up.
Retina.
2011;31(8):1598-602.
doi:
10.1097/IAE.0b013e31820d3f28. PubMed PMID: 21478804.
92.
Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al.
Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal
vasculopathy: one-year results of a prospective case series. Ophthalmology.
2004;111(8):1576-84. doi: 10.1016/j.ophtha.2003.12.056. PubMed PMID:
15288991.
93.
Miyamoto N, Mandai M, Oishi A, Nakai S, Honda S, Hirashima T, et
al. Long-term results of photodynamic therapy or ranibizumab for polypoidal
choroidal vasculopathy in LAPTOP study. Br J Ophthalmol. 2019;103(6):8448. doi: 10.1136/bjophthalmol-2018-312419. PubMed PMID: 30077969.
94.
Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, et al.
Hemorrhagic complications after photodynamic therapy for polypoidal
choroidal
vasculopathy.
Retina.
2007;27(3):335-41.
doi:
10.1097/01.iae.0000233647.78726.46. PubMed PMID: 17460589.
95.
Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk
P, et al. Efficacy and Safety of Ranibizumab With or Without Verteporfin
Photodynamic
Therapy
for
Polypoidal
Choroidal
Vasculopathy:
Randomized Clinical Trial. JAMA Ophthalmol. 2017;135(11):1206-13. doi:
10.1001/jamaophthalmol.2017.4030. PubMed PMID: 28983556; PubMed
Central PMCID: PMCPMC5710379.
83
96.
Miyata M, Ooto S, Yamashiro K, Tamura H, Hata M, Ueda-Arakawa
N, et al. Five-year visual outcomes after anti-VEGF therapy with or without
photodynamic
therapy
for
polypoidal
choroidal
vasculopathy.
Br
Ophthalmol. 2018. doi: 10.1136/bjophthalmol-2018-311963. PubMed PMID:
29875231.
97.
Coscas G, Lupidi M, Coscas F, Benjelloun F, Zerbib J, Dirani A, et al.
Toward a specific classification of polypoidal choroidal vasculopathy:
idiopathic disease or subtype of age-related macular degeneration. Invest
Ophthalmol Vis Sci. 2015;56(5):3187-95. doi: 10.1167/iovs.14-16236. PubMed
PMID: 26024102.
98.
Tan CS, Ngo WK, Lim LW, Lim TH. A novel classification of the
vascular patterns of polypoidal choroidal vasculopathy and its relation to
clinical
outcomes.
Br
Ophthalmol.
2014;98(11):1528-33.
doi:
10.1136/bjophthalmol-2014-305059. PubMed PMID: 24997181.
99.
Yanagi Y, Ting DSW, Ng WY, Lee SY, Mathur R, Chan CM, et al.
Choroidal Vascular Hyperpermeability as a Predictor of Treatment Response
for Polypoidal Choroidal Vasculopathy. Retina. 2018;38(8):1509-17. doi:
10.1097/IAE.0000000000001758. PubMed PMID: 28704255.
100.
Azuma K, Tan X, Asano S, Shimizu K, Ogawa A, Inoue T, et al. The
association of choroidal structure and its response to anti-VEGF treatment
with the short-time outcome in pachychoroid neovasculopathy. PLoS One.
2019;14(2):e0212055. doi: 10.1371/journal.pone.0212055. PubMed PMID:
30763369; PubMed Central PMCID: PMCPMC6375588.
101.
Baek J, Lee JH, Jeon S, Lee WK. Choroidal morphology and short-
term outcomes of combination photodynamic therapy in polypoidal choroidal
vasculopathy. Eye (Lond). 2019;33(3):419-27. doi: 10.1038/s41433-018-0228-7.
PubMed PMID: 30305706; PubMed Central PMCID: PMCPMC6460701.
102.
Bressler NM, Treatment of Age-Related Macular Degeneration with
Photodynamic Therapy Study G. Photodynamic therapy of subfoveal
choroidal neovascularization in age-related macular degeneration with
verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch
Ophthalmol. 2001;119(2):198-207. PubMed PMID: 11176980.
103.
Teo KYC, Yanagi Y, Lee SY, Yeo IYS, Tan GSW, Mathur R, et al.
Comparison of Optical Coherence Tomography Angiographic Changes after
84
Anti-Vascular Endothelial Growth Factor Therapy Alone or in Combination
with Photodynamic Therapy in Polypoidal Choroidal Vasculopathy. Retina.
2018;38(9):1675-87. doi: 10.1097/IAE.0000000000001776. PubMed PMID:
28767554.
104.
of
Verteporfin In Photodynamic Therapy Study G. Verteporfin therapy
subfoveal
choroidal
neovascularization
in
age-related
macular
degeneration: two-year results of a randomized clinical trial including lesions
with occult with no classic choroidal neovascularization--verteporfin in
photodynamic therapy report 2. Am J Ophthalmol. 2001;131(5):541-60. doi:
10.1016/s0002-9394(01)00967-9. PubMed PMID: 11336929.
105.
Japanese Study Group of Polypoidal Choroidal V. [Criteria for
diagnosis of polypoidal choroidal vasculopathy]. Nippon Ganka Gakkai
Zasshi. 2005;109(7):417-27. PubMed PMID: 16050460.
106.
Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK,
et al. Vascular endothelial growth factor expression in the retinal pigment
epithelium is essential for choriocapillaris development and visual function.
Am J Pathol. 2005;167(5):1451-9. doi: 10.1016/S0002-9440(10)61231-X.
PubMed PMID: 16251428; PubMed Central PMCID: PMCPMC1603772.
107.
Sakurada Y, Sugiyama A, Tanabe N, Kikushima W, Kume A, Iijima
H. Choroidal Thickness as a Prognostic Factor of Photodynamic Therapy with
Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy. Retina.
2017;37(10):1866-72. doi: 10.1097/IAE.0000000000001427. PubMed PMID:
28002268.
108.
Kuroda Y, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Oishi A, et
al. Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular
Degeneration After Ranibizumab Treatment. Am J Ophthalmol. 2016;161:94103 e1. doi: 10.1016/j.ajo.2015.09.032. PubMed PMID: 26432927.
109.
Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore
PA. An essential role for RPE-derived soluble VEGF in the maintenance of
the choriocapillaris. Proc Natl Acad Sci U S A. 2009;106(44):18751-6. doi:
10.1073/pnas.0905010106. PubMed PMID: 19841260; PubMed Central
PMCID: PMCPMC2774033.
110.
Hiroe T, Kishi S. Dilatation of Asymmetric Vortex Vein in Central
Serous
Chorioretinopathy.
Ophthalmol
85
Retina.
2018;2(2):152-61.
doi:
10.1016/j.oret.2017.05.013. PubMed PMID: 31047342.
111.
Kishi S, Matsumoto H, Sonoda S, Hiroe T, Sakamoto T, Akiyama H.
Geographic filling delay of the choriocapillaris in the region of dilated
...
論文の公開元へ
